CER-001 Atherosclerosis Regression ACS Trial

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 301 participants.

Also called NCT02484378

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 301 participants (enrolled count) (from the registry)
Sponsor
Cerenis Therapeutics, SA (from the registry)
Registry
  • NCT NCT02484378
Other papers using this trial's data
  • Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial JAMA cardiology, 2018-09-01 DOI, PubMed 30046828, PMC6233644 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Hungary, Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02484378. Randomized; quadruple masking; primary purpose treatment. Start 2015-08 (actual); primary completion 2016-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CER-001 Atherosclerosis Regression ACS Trial
Acronym
CARAT
Condition
Acute Coronary Syndromes
Intervention (Drug)
CER-001
Intervention (Drug)
Placebo
Lead sponsor
Cerenis Therapeutics, SA (class: industry)
Collaborator
South Australian Health and Medical Research Institute (class: other)

Record details

Record id
cardio:ct-nct02484378
Content hash
68da87fbb93e14f10fd06fcea49952a886d0bd935b673bf7b172673a3ad21025